ES2181689T3 - Variantes del factor de crecimiento de hepatocitos. - Google Patents

Variantes del factor de crecimiento de hepatocitos.

Info

Publication number
ES2181689T3
ES2181689T3 ES93911339T ES93911339T ES2181689T3 ES 2181689 T3 ES2181689 T3 ES 2181689T3 ES 93911339 T ES93911339 T ES 93911339T ES 93911339 T ES93911339 T ES 93911339T ES 2181689 T3 ES2181689 T3 ES 2181689T3
Authority
ES
Spain
Prior art keywords
variants
hgf
hepatocits
growth factor
hepatocite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93911339T
Other languages
English (en)
Inventor
Paul J Godowski
Nathalie A Lokker
Melanie R Mark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/884,811 external-priority patent/US5316921A/en
Priority claimed from US07/885,971 external-priority patent/US5328837A/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2181689T3 publication Critical patent/ES2181689T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A LAS VARIANTES DE LA SECUENCIA AMINOACIDA DEL FACTOR DE DESARROLLO DE HEPATOCITOS (HGF). LAS VARIANTES PREFERIDAS SON RESISTENTES A LA SEGMENTACION PROTEOLITICA POR ENZIMAS CAPACES DE CONVERSION IN VIVO DEL HGF DENTRO DE SU FORMA DE DOS CADENAS Y/O CONTIENEN UNA MUTACION SIN DOMINIO DE PROTEASA DEL HGF.
ES93911339T 1992-05-18 1993-05-17 Variantes del factor de crecimiento de hepatocitos. Expired - Lifetime ES2181689T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/884,811 US5316921A (en) 1992-05-18 1992-05-18 Single-chain hepatocyte growth factor variants
US07/885,971 US5328837A (en) 1992-05-18 1992-05-18 Hepatocyte growth factor protease domain variants

Publications (1)

Publication Number Publication Date
ES2181689T3 true ES2181689T3 (es) 2003-03-01

Family

ID=27128741

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93911339T Expired - Lifetime ES2181689T3 (es) 1992-05-18 1993-05-17 Variantes del factor de crecimiento de hepatocitos.

Country Status (10)

Country Link
US (1) US5547856A (es)
EP (1) EP0642580B1 (es)
JP (2) JPH07508420A (es)
AT (1) ATE222603T1 (es)
CA (1) CA2118012A1 (es)
DE (1) DE69332221T2 (es)
DK (1) DK0642580T3 (es)
ES (1) ES2181689T3 (es)
PT (1) PT642580E (es)
WO (1) WO1993023541A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566098B1 (en) 1990-09-14 2003-05-20 The United States Of America As Represented By The Department Of Health And Human Services DNA encoding truncated hepatocyte growth factor variants
DE69334159D1 (de) * 1992-09-18 2007-09-13 Us Gov Health & Human Serv Medizinische Verwendung eines Antikörpers oder eines Antikörperfragments gegen die extrazelluläre Domäne von Met zur Prevention von Metastasen
DE69531673T2 (de) * 1994-12-27 2004-07-08 Daiichi Pharmaceutical Co., Ltd. Tcf mutante
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
JP3832674B2 (ja) * 1995-10-24 2006-10-11 敏一 中村 抗癌剤
US6855685B2 (en) 1995-10-24 2005-02-15 Toshikazu Nakamura Anti-cancer agent
WO1998019696A1 (en) * 1996-11-05 1998-05-14 Smithkline Beecham Corporation Hepatocyte growth factor antagonists
JP4006058B2 (ja) * 1997-03-11 2007-11-14 第一三共株式会社 多臓器不全予防及び／又は治療剤
AU734766B2 (en) * 1997-03-14 2001-06-21 Atlas Pharmaceuticals Inc. Agent for preventing and/or treating cachexia
GB9709453D0 (en) * 1997-05-10 1997-07-02 Imp Cancer Res Tech Polypedtides and their use in therapy
ITMI980179A1 (it) * 1998-01-30 1999-07-30 Dompe Spa Proteine ricombinanti derivate da hgf e msp
ITMI980180A1 (it) * 1998-01-30 1999-07-30 Dompe Spa Proteine ricombinanti derivate da hgf e msp
US20020136721A1 (en) * 1998-02-17 2002-09-26 Schwall Ralph H. Hepatocyte growth factor receptor antagonists and uses thereof
WO2001023598A1 (en) * 1999-09-27 2001-04-05 Human Genome Sciences, Inc. 41 human secreted proteins
US20080241835A1 (en) * 1999-11-01 2008-10-02 Genentech, Inc. Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
CA2392366A1 (en) * 1999-11-24 2001-05-31 Human Genome Sciences, Inc. Major intrinsic protein (mip)-like polynucleotides, polypeptides, and antibodies
EP1293511A4 (en) * 2000-06-22 2005-11-30 Nippon Zenyaku Kogyo Ltd GROWTH FACTOR FOR CANINE HEPATIC CELLS
EP1234583A1 (en) 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
GB0110430D0 (en) 2001-04-27 2001-06-20 Medical Res Council Protein variants and uses thereof
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US20050100963A1 (en) 2002-03-01 2005-05-12 Dyax Corporation KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
AU2003253632A1 (en) * 2002-06-10 2003-12-22 Idec Pharmaceuticals Corporation Genes overexpressed by ovarian cancer and their use in developing novel therapeutics
AU2003277283A1 (en) * 2002-10-07 2004-05-04 Genentech, Inc. Hepatocyte growth factor variants
PT2949658T (pt) * 2003-03-03 2018-10-18 Bracco Suisse Sa Péptidos que ligam especificamente o recetor de hgf (cmet) e utilizações dos mesmos
US7407660B2 (en) * 2003-04-16 2008-08-05 Genentech, Inc. Methods and compositions for selective modulation of vascularization
CA2549878A1 (en) * 2003-12-16 2005-06-30 Toshikazu Nakamura Glycosylation-deficient hepatocyte growth factor
KR100956913B1 (ko) * 2003-12-19 2010-05-11 제넨테크, 인크. 치료제로서 유용한 일가 항체 단편
US7807177B2 (en) * 2004-01-27 2010-10-05 Toshikazu Nakamura Segment of glycosylation-deficient HGFalpha-chain
JP2007525981A (ja) 2004-03-03 2007-09-13 エフ．ホフマン−ラ　ロシュ　アーゲー 肝細胞成長因子のｎ末端フラグメントを組み換え発現するための方法
ES2297673T3 (es) 2004-03-03 2008-05-01 F. Hoffmann-La Roche Ag Metodo para la purificacion de un fragmento n-terminal del factor de crecimiento de hepatocitos.
EP1773885B1 (en) 2004-08-05 2010-04-21 Genentech, Inc. Humanized anti-cmet antagonists
SG161281A1 (en) 2005-04-15 2010-05-27 Genentech Inc Hgf beta chain variants
EP2260056A1 (en) * 2008-03-06 2010-12-15 Genentech, Inc. Combination therapy with c-met and her antagonists
RU2013155695A (ru) 2011-06-30 2015-08-10 Дженентек, Инк. Препараты антител против с-мет
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
KR102793810B1 (ko) * 2017-08-04 2025-04-11 가톨릭대학교 산학협력단 간세포성장인자를 발현하는 중간엽줄기세포를 유효성분으로 포함하는 혈관계 질환 예방 또는 치료용 약학적 조성물
CN109535243B (zh) * 2019-01-07 2019-09-24 北京诺思兰德生物技术股份有限公司 人肝细胞生长因子突变体及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2814981C3 (de) * 1978-04-07 1981-08-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Faktor zur Stimulation der Proliferationsrate von Leberzellen
DE2914903C2 (de) * 1979-04-12 1981-08-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Leberzellwachstumfaktor
JPS5862116A (ja) * 1981-10-09 1983-04-13 Mitsubishi Chem Ind Ltd 肝細胞の増殖促進物質
JPS6045534A (ja) * 1983-08-22 1985-03-12 Otsuka Pharmaceut Co Ltd 肝実質細胞増殖因子
JPS60243019A (ja) * 1984-05-17 1985-12-03 Mitsubishi Chem Ind Ltd 肝細胞増殖因子
JPH0635480B2 (ja) * 1985-08-23 1994-05-11 大塚製薬株式会社 肝実質細胞増殖因子
JPS62161730A (ja) * 1986-01-10 1987-07-17 Mitsubishi Chem Ind Ltd 細胞増殖因子の産生誘発剤
JP2564486B2 (ja) * 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
US4851341A (en) * 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
ES2005159A6 (es) * 1987-04-14 1989-03-01 Inst Llorente S A Procedimiento para diagnostico y seguimiento de hepatopatias mediante determinacion de factor de crecimiento hepatico en plasma yno suero sanguineo.
JPS6427491A (en) * 1987-07-14 1989-01-30 Yasushi Daikuhara Monoclonal antibody
JPH02213A (ja) * 1987-10-19 1990-01-05 Taiho Yakuhin Kogyo Kk 生理活性ペプチド持続製剤
JP3030312B2 (ja) * 1988-12-12 2000-04-10 敏一 中村 成熟肝実質細胞増殖因子（ｉ）
US5179078A (en) * 1989-05-12 1993-01-12 Dana Farber Cancer Institute Method of suppressing tumor formation in vivo
JPH03130091A (ja) * 1989-06-05 1991-06-03 Toyobo Co Ltd 組換ヒト肝実質細胞増殖因子
JP2706704B2 (ja) * 1989-06-05 1998-01-28 敏一 中村 組換ヒト肝実質細胞増殖因子
CA2022752C (en) * 1989-08-11 1998-07-07 Naomi Kitamura Hepatic parenchymal cell growth factor, gene encoding the same, process for producing the factor, and transformants producing the factor
JPH03204899A (ja) * 1989-09-21 1991-09-06 Otsuka Pharmaceut Co Ltd ヒト肝再生因子、そのｄｎａ塩基配列、該配列を含むプラスミド及び形質転換体並びにリコンビナント肝再生因子
JPH03255096A (ja) * 1990-03-01 1991-11-13 Toyobo Co Ltd 組換ラット肝実質細胞増殖因子
US5235043A (en) * 1990-04-06 1993-08-10 Synergen, Inc. Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins
JPH0413696A (ja) * 1990-05-08 1992-01-17 Mochida Pharmaceut Co Ltd 新規生理活性物質
JP2784455B2 (ja) * 1990-05-09 1998-08-06 敏一 中村 肝硬変治療剤
JPH0436189A (ja) * 1990-05-30 1992-02-06 Otsuka Pharmaceut Co Ltd 肝細胞増殖因子の製造方法
DE69133492T2 (de) * 1990-06-11 2006-08-10 Nakamura, Toshikazu Rekombinanter menschlicher Hepatozytwachstumsfaktor und Verfahren zu seiner Herstellung
JP2750372B2 (ja) * 1990-06-19 1998-05-13 敏一 中村 賢疾患治療剤
EP0539590B1 (en) * 1990-07-13 1999-03-31 Snow Brand Milk Products Co., Ltd. Plasmid containing dna which codes for the amino acid sequence of tcf-ii, transformed cell, and production of physiologically active substance by using the same
JPH04120097A (ja) * 1990-09-07 1992-04-21 Agency Of Ind Science & Technol 肝細胞増殖因子
DE69133349T2 (de) * 1990-09-14 2004-10-07 Us Health Ein nicht-mitogener kompetitiver hgf-antagonist
JP3072628B2 (ja) * 1990-11-19 2000-07-31 敏一 中村 ヒト肝実質細胞増殖因子をコードする染色体ｄｎａ
JP3200609B2 (ja) * 1990-12-28 2001-08-20 敏一 中村 上皮細胞増殖促進剤
US5316921A (en) * 1992-05-18 1994-05-31 Genentech, Inc. Single-chain hepatocyte growth factor variants
US5328837A (en) * 1992-05-18 1994-07-12 Genentech, Inc. Hepatocyte growth factor protease domain variants

Also Published As

Publication number Publication date
DK0642580T3 (da) 2002-12-23
JPH07508420A (ja) 1995-09-21
WO1993023541A1 (en) 1993-11-25
EP0642580A1 (en) 1995-03-15
DE69332221T2 (de) 2003-04-17
CA2118012A1 (en) 1993-11-25
PT642580E (pt) 2003-01-31
EP0642580B1 (en) 2002-08-21
DE69332221D1 (de) 2002-09-26
ATE222603T1 (de) 2002-09-15
JP2004000236A (ja) 2004-01-08
US5547856A (en) 1996-08-20

Similar Documents

Publication Publication Date Title
ES2181689T3 (es) Variantes del factor de crecimiento de hepatocitos.
FI932561A0 (fi) Proteiner med foeraendrade epitoper och foerfaranden foer deras framstaellning
LTIP888A (lt) Polietilenglikolio-interferono konjugatai
EP0871664A4 (en) NEW CHEMOKIN FOR MOBILIZING STEM CELLS
DE69023948D1 (de) Herstellung von peroxidhaltigen Perfluorpolyethern.
BR9100752A (pt) Fluoroelastomeros com processabilidade e curabilidade aperfeicoadas resistentes as bases
NO971875L (no) Cathepsin 02 protease
IT8820649A0 (it) Processo perfezionato per laproduzione di perfluoropolieteri costituiti sostanzialmente da unita' perfluoossietileniche e perfluoroossipropileniche.
IT1237999B (it) Trattamento di malattie associate ad infezioni di hiv
CO5050392A1 (es) Pestivirus atenuados
EP0605073A3 (en) Molecular cloning and expression of neutral protease genes.
ITRM910430A1 (it) Composizioni farmaceutiche di somatostatina con assorbimento migliorato, loro preparazione e loro impiego
ATE359768T1 (de) Pflaster
DE68918033D1 (de) Schutz zur Abnutzungsverringerung von Fingerhutrohren.
ES2192556T3 (es) Mejoras en o relativas a la vacuna de la malaria.
ES2095233T3 (es) Produccion eficaz de proteasa mutante.
ATE93745T1 (de) Konzentrierte pumpbare polyethercarboxylate.
FI885301A7 (fi) Tekijä VIII:n puhdistuksessa käyttökelpoisia peptidejä
DE69002496D1 (de) Herstellung von fluorphenolen.
EP0666841A1 (en) SUCCINOYLHYDROXYÄTHYLAMINOSULFAMID ACID DERIVATIVES AND THEIR USE AS RETROVIRAL PROTEASE INHIBITORS.
ES2177721T3 (es) Gonadotropinas con puentes disulforono nativos.
IT231814Y1 (it) Anello in metallo prezioso o non,provvisto alla sommita' di un bilanciere oscillante per mostrare o nascondere due pietre preziose
DE3880110D1 (de) Herstellung von m-aminophenol.
GR1001393B (el) Παράγωγα ιμιδαζο[2,1-Β] 3] βενζαζεπίνης, συν?έσεις και μέ?οδος χρήσεως.
CO4790108A1 (es) Formula para hacer expandir el cemento